$CELG Recent News Major U.S. benchmarks challenge

New Post Public Reply Private Reply Replies (0) Message Board

Jan 28, 2015 at 11:09 AM

$CELG Recent News

Major U.S. benchmarks challenge last-ditch support 11:31 a.m. Jan. 20, 2015 - Michael Ashbaugh
Major U.S. benchmarks challenge last-ditch support 11:09 a.m. Jan. 20, 2015 - Michael Ashbaugh
Some of the Nasdaq’s leading lights have begun to dim 2:02 p.m. Jan. 15, 2015 - The Trading Deck
GameStop shares rally on strong holiday sales 5:48 p.m. Jan. 13, 2015 - MarketWatch
Celgene shares gain 3.6% to top S&P 500 9:40 a.m. Jan. 13, 2015 - Sue Chang
Three investments to own and three to 6:00 a.m. Jan. 13, 2015 - Howard Gold
Updates, advisories and surprises 12:31 p.m. Jan. 12, 2015 - MarketWatch
Celgene's 2015 profit outlook is below forecasts 12:18 p.m. Jan. 12, 2015 - MarketWatch.com
Celgene's stock rises, but off highs after profit outlook 11:48 a.m. Jan. 12, 2015 - Tomi Kilgore
Celgene's stock gains 1.2% after Q4 profit view tops expectations 11:26 a.m. Jan. 12, 2015 - Tomi Kilgore
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
GoPro, Gilead Sciences, Celgene gain 11:27 a.m. Dec. 26, 2014 - MarketWatch
Dow ekes out gain for 37th record close of 2014 2:55 p.m. Dec. 24, 2014 - Carla Mozee
GoPro, Adamas climb, Cal-Maine slides 10:06 a.m. Dec. 24, 2014 - MarketWatch
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Dec. 23, 2014 - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:10 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:41 p.m. Dec. 8, 2014 - Sue Chang
The S&P 500 recorded its biggest drop in nearly 7 weeks 4:33 p.m. Dec. 8, 2014 - Sara Sjolin

Amgen Beats on Q4 Earnings & Revenues, Maintains Outlook - Analyst Blog 10:00 a.m. Today - Zacks.com
Gilead Includes Pan-Genotypic Agent in HCV Licensing Deals - Analyst Blog 6:55 p.m. Jan. 27, 2015 - Zacks.com
The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst Blog 6:30 p.m. Jan. 27, 2015 - Zacks.com
Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog 4:45 p.m. Jan. 27, 2015 - Zacks.com
Do You Believe Me Now? 10:59 a.m. Jan. 27, 2015 - Seeking Alpha
Pfizer Beats on Q4 Earnings, Guides Below Expectations - Analyst Blog 10:19 a.m. Jan. 27, 2015 - Zacks.com
Celgene: Could You Be More Like Gilead, Please? 7:47 a.m. Jan. 27, 2015 - Seeking Alpha
Big Cap Stocks Mylan, American Tower Near Buy Points 5:42 p.m. Jan. 26, 2015 - Investors Business Daily
TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog 12:00 p.m. Jan. 26, 2015 - Zacks.com
Zillow Is In Limbo - Cramer's Lightning Round (1/23/15) 7:42 a.m. Jan. 26, 2015 - Seeking Alpha
The Coming Week Is The Most Important - Cramer's Mad Money (1/23/15) 7:38 a.m. Jan. 26, 2015 - Seeking Alpha
Can CAR-T Therapy Live Up To The Biotech IPO Hype? 7:02 a.m. Jan. 26, 2015 - Investors Business Daily
Apple, Facebook Lead This Week's IBD 50 Earnings 7:02 a.m. Jan. 26, 2015 - Investors Business Daily
The Best Play in Biotechs: M&A 5:05 a.m. Jan. 26, 2015 - InvestorPlace.com
'Mad Money' Lightning Round: Constellation Brands the New King in Town 6:00 a.m. Jan. 24, 2015 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:22 p.m. Jan. 23, 2015 - TheStreet.com
European Ad Comm supports expanded label for Abraxane 7:44 a.m. Jan. 23, 2015 - Seeking Alpha
Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog 5:40 p.m. Jan. 22, 2015 - Zacks.com
Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog 4:10 p.m. Jan. 22, 2015 - Zacks.com
Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog 4:00 p.m. Jan. 22, 2015 - Zacks.com

Celgene Corporation to Webcast at Upcoming Investor Conferences 8:30 a.m. Jan. 27, 2015 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer 7:19 a.m. Jan. 23, 2015 - BusinessWire - BZX
Critical Alerts For Apple, VoxelJet, Celgene, TASER International and Finisar Released By InvestorsObserver 9:31 a.m. Jan. 22, 2015 - PR Newswire - PRF
Insider Trading Buzz for Alcoa, Southwestern Energy, Celgene, Micron, FXCM, and Twitter 8:45 a.m. Jan. 21, 2015 - PR Newswire - PRF
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 12:24 p.m. Jan. 16, 2015 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis 9:10 a.m. Jan. 16, 2015 - BusinessWire - BZX
Hogging the Limelight: New Research on Netlist, Celgene, Jamba, Citigroup and Tilly's 8:40 a.m. Jan. 14, 2015 - PR Newswire - PRF
Biotechs to Follow in 2015 off Fresh Insider Moves 10:00 a.m. Jan. 6, 2015 - ACCESSWIRE
Celgene Corporation to Present at the 33rd Annual J.P. Morgan Healthcare Conference 8:31 a.m. Jan. 6, 2015 - BusinessWire - BZX
Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

iTLC Traffic Systems Expand Global Reach at APTA 2026

APTA 2026: The Launchpad for Intelligent Traffic Control Forget the days of manual traffic chaos—by the sounds of it, smart intersections are ready to rule the roads. Today's chatter at APTA 2026 in Chicago was a whirlwind of ideas, all centered around how ICP DAS and Towards Buddha Co., Ltd. plan to shake up traffic management globally with their iTLC Intelligent...

Main Street Merger Faces Scrutiny: What It Means for Shareholders

Under the Radar, but Not for Long Ah, mergers—those grand gestures in corporate America that promise growth, synergy, and shareholder value. But not every deal is a head-turner; some fly under the radar until someone grabs the magnifying glass. And that's exactly what's happening with Main Street Financial Services Corp.'s (OTC: MSWV) proposed merger with First...

China-Malaysia Youth Dialogue: Tackling Ocean Challenges

Building Bridges Across Waters These aren't the afternoons of trading stocks, folks—this one dives into the depths of the ocean and the tumultuous waters between China and Malaysia. October 30 saw the China-Malaysia Youth Ocean Dialogue take place at the China Media Group Sanya Studio, bringing together some sharp minds from both nations, tackling something that goes...

UBCF Strikes Big in Times Square with New Billboards

From the Shadows to the Spotlight Ever seen someone step up to the plate and knock it out of the park? That's what the United Breast Cancer Foundation (UBCF) is doing by plastering their mission right across Times Square. Talk about grabbing the bull by the horns, eh? With not one, but two billboards now gracing one of the globe's most iconic public spaces, they've...

NABEP's Strategic Push: 41 Rigs to Bolster Output

On The Ground: NABEP's Expanding Venezuelan Presence Think of oil production as a high-stakes poker game where each drill and rig is a well-placed bet. North American Blue Energy Partners (NABEP) is going all in on Venezuela, boosting their rig fleet and pushing production capacity to new heights. Set your sights on November when NABEP's in-country fleet will hit 41 rigs...

ModelBest & OpenBMB Unveil Open-Source OCR Models

A New Frontier in Document Parsing Just when you thought document parsing couldn't get any more advanced, ModelBest and OpenBMB come along with a game-changing release: the MiniCPM-OCR series. This duo of dynamite models, MiniCPM-OCR 1.0 and Jev, is all about taking the efficiency and performance expectations for open-source OCR models up a couple of notches. If you're an...

Zhimeng Biopharma Hits Key Milestone in ALS Drug Trial

Pivotal Point for Zhimeng's ALS Efforts Folks, get this—Zhimeng Biopharma's rolling out the big guns here with a significant step forward in their ALS treatment quest. This company just wrapped up patient enrollment for their next-gen ALS drug, CB03-154. We're talking about 255 patients now on board for a Phase 2/3 trial. The ground's shaking a bit because this...

HanAll F&B Pioneers New Path for Domestic Rice Noodles

New Spin on an Old Favorite: Rice Noodles Forget about the same old wheat noodles clogging up the pantry. HanAll F&B is revamping the noodle game with a homegrown twist, setting sights on a future where Korean rice isn't just for steaming, soup, or sushi. This outfit from Taebaek, Gangwon, has got its hands deep in the rice flour, finessing a patent that aims to make...

Bass Angler Matt Robertson Reels in Record $1.25M Prize

A New Era for Bass Fishing Payouts Who would have thought we'd see the day when bass fishing turned out to be as lucrative as a Wall Street handshake? But here we are, with Matt Robertson hauling in a whopping $1.25 million prize at World Bass Enterprises' first "The Champions" Tournament. We're not talking chump change here—this is the real deal in a sport often...

NIDS Aims Global with CES 2027, Boosts Sensor Supply

Pushing Boundaries at CES 2027 Kicking into high gear, NIDS Co., Ltd. is eyeing the CES 2027 stage like it's their personal gold rush. Already a heavyweight in environmental sensors, the company is all set to seize fresh international opportunities and expand their B2B supply footprint worldwide. Already Turning Heads Founded back in 2000, NIDS ain't new to the sensor...